SYK
STRYKER CORP
NYSE · Healthcare · Medical - Devices · US
$341.49
+9.96%Year over year
Reported trailing growth
- Revenue
- +7.9%
- EBITDA
- +37.7%
- EBIT
- +9.8%
- EPS
- +22.6%
- Free cash flow
- +12.3%
- Operating cash flow
- +12.7%
Forward estimates
Based on analyst estimates
- Revenue
- +7.2%
- EBITDA
- +33.9%
- EPS
- +69.2%
Three-year CAGR
- Revenue
- +10.8%
- EBITDA
- +16.3%
- EBIT
- +9.4%
- Net income
- +11.2%
- EPS
- +10.9%
- Free cash flow
- +28.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026